Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900644 | 0.84 | CES1 (0.55) | CES1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL9317591 | 0.84 | MAPK1 (0.56) | CES1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL7697986 | 0.83 | ALOX5 (0.51) | CES1TDP1KMT2APOLBMEN1 | |
| SCHEMBL28634355 | 0.82 | CES1 (0.53) | CES1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL2402587 | 0.82 | ALDH1A1 (0.46) | CA1CA2TDP1ALDH1A1TSHR | |
| SCHEMBL15751973 | 0.81 | ALOX5 (0.54) | CES1TDP1PTPN2PTPN1CES2 | |
| SCHEMBL13778136 | 0.81 | MAPK1 (0.53) | CES1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL1436249 | 0.80 | CES1 (0.65) | CES1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL254773 | 0.80 | CES1 (0.65) | CES1CA1CA2TDP1ALDH1A1 | |
| SCHEMBL13778239 | 0.80 | TDP1 (0.53) | CES1CA1CA2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0223588-B1 | PROCESS FOR THE PREPARATION OF BETA-LACTAM COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-12 | — | — | EP | claimed |
| US-4833145-A | 4(3H)-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-05-23 | — | — | US | claimed |
| EP-1638538-B1 | DOSAGE FORM | THE UNIV OF HULL (GB) | 2018-02-14 | — | — | EP | disclosed |
| US-9169258-B2 | Doripenem intermediate compound, preparation process therefor and use thereof, and preparation process for doripenem | SHENZHEN HAIBIN PHARMACEUTICAL CO., LTD. (CN) | 2015-10-27 | — | — | US | disclosed |
| US-20150038700-A1 | DORIPENEM INTERMEDIATE COMPOUND, PREPARATION PROCESS THEREFOR AND USE THEREOF, AND PREPARATION PROCESS FOR DORIPENEM | SHENZHEN HAIBIN PHARMACEUTICAL CO., LTD. (CN) | 2015-02-05 | — | — | US | disclosed |
| CN-1842325-B | Dosage forms | UNIV HULL | 2012-02-29 | — | — | CN | disclosed |
| US-20090281111-A1 | 3-HYDROXY GEPIRONE FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7608270-B2 | Active ingredient bound to or encapsulated within exine coating of spores from plant, moss, fungus or algae; oral delivery with rapid release to blood stream | UNIVERSITY OF HULL (GB) | 2009-10-27 | — | — | US | disclosed |
| CN-1842325-A | Dosage forms | UNIV HULL (GB) | 2006-10-04 | — | — | CN | disclosed |
| EP-1638538-A2 | DOSAGE FORM | The University of Hull (GB) | 2006-03-29 | — | — | EP | disclosed |
| US-20050002963-A1 | Dosage form | SPOROMEX LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| EP-0547031-A1 | N-protected-(S)-isoserine compounds | SCHERING CORPORATION (US) | 1993-06-16 | — | — | EP | disclosed |
| EP-0478707-A1 | IMPROVED PROCESS FOR PREPARING ISEPAMICIN | SCHERING CORPORATION (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0405820-A2 | Improved process for preparing isepamicin | SCHERING CORPORATION (US) | 1991-01-02 | — | — | EP | disclosed |
| WO-1990015810-A2 | IMPROVED PROCESS FOR PREPARING ISEPAMICIN | SCHERING CORPORATION (US) | 1990-12-27 | — | — | WO | disclosed |
| US-4897489-A | 2-/5-OXO-2-TETRAHYDROFURANY4-3-OXOISOXOL-IDINE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-30 | — | — | US | disclosed |
| US-4851422-A | Antibiotic 2-(3-oxo-2-isoxazolidinyl)-5-oxo-2-tetrahydrofuran-carboxylates | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0219923-A1 | Antibiotic derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0191989-A1 | Antibiotic isoxazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-08-27 | — | — | EP | disclosed |
| EP-0016900-B1 | INTERMEDIATES IN THE PREPARATION OF CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE | CIBA-GEIGY AG (CH) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281111-A1 | 3-HYDROXY GEPIRONE FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER AND SEXUAL DYSFUNCTION | HTR1D, HTR3A, HTR3E | CES1 1460/4885CA1 4863/4885CA2 4865/4885 |
| US-20150038700-A1 | DORIPENEM INTERMEDIATE COMPOUND, PREPARATION PROCESS THEREFOR AND USE THEREOF, AND PREPARATION PROCESS FOR DORIPENEM | HADHB, PDHB, FARSB | CES1 715/4885CA1 3731/4885CA2 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.